Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease
Nataliya P. Buxbaum, … , Remy J. Bosselut, Ronald E. Gress
Nataliya P. Buxbaum, … , Remy J. Bosselut, Ronald E. Gress
Published June 15, 2017
Citation Information: JCI Insight. 2017;2(12):e92851. https://doi.org/10.1172/jci.insight.92851.
View: Text | PDF
Resource and Technical Advance Immunology Transplantation

In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease

  • Text
  • PDF
Abstract

Hematopoietic stem cell transplantation (HSCT) offers a cure for cancers that are refractory to chemotherapy and radiation. Most HSCT recipients develop chronic graft-versus-host disease (cGVHD), a systemic alloimmune attack on host organs. Diagnosis is based on clinical signs and symptoms, as biopsies are risky. T cells are central to the biology of cGVHD. We found that a low Treg/CD4+ T effector memory (Tem) ratio in circulation, lymphoid, and target organs identified early and established mouse cGVHD. Using deuterated water labeling to measure multicompartment in vivo kinetics of these subsets, we show robust Tem and Treg proliferation in lymphoid and target organs, while Tregs undergo apoptosis in target organs. Since deuterium enrichment into DNA serves as a proxy for cell proliferation, we developed a whole-body clinically relevant deuterium MRI approach to nonradioactively detect cGVHD and potentially allow imaging of other diseases characterized by rapidly proliferating cells.

Authors

Nataliya P. Buxbaum, Donald E. Farthing, Natella Maglakelidze, Martin Lizak, Hellmut Merkle, Andrea C. Carpenter, Brittany U. Oliver, Veena Kapoor, Ehydel Castro, Gregory A. Swan, Liliane M. dos Santos, Nicolas J. Bouladoux, Catherine V. Bare, Francis A. Flomerfelt, Michael A. Eckhaus, William G. Telford, Yasmine Belkaid, Remy J. Bosselut, Ronald E. Gress

×

Figure 3

Cell gain kinetics for Tregs in the spleen and liver for allogeneic (allo) and syngeneic (syn) hematopoietic stem cell transplant recipients (HSCT).

Options: View larger image (or click on image) Download as PowerPoint
Cell gain kinetics for Tregs in the spleen and liver for allogeneic (all...
(A) Percentage of new Tregs in the spleen for each cohort at day +14 and +28, following 7 days of labeling. Data for 5 independent experiments pooled for day +7 to +14 analysis, and 3 independent experiments for day +21 to +28 analysis. (B) Percentage of new Tregs in the liver for each cohort measured at day +14 and +28, following 7 days of labeling. Data for 3 independent experiments were pooled for day +7 to +14 analysis and 2 independent experiments for day +21 to +28 analysis. (C) Percentage of new Treg and Tem cells in the allogeneic spleen measured at day +14 and +28, following 7 days of labeling. Data for 5 independent experiments pooled for the day +7 to +14 analysis, and 3 independent experiments for day +21 to +28 analysis. (D) Percentage of new Treg and Tem cells in the allogeneic liver measured at day +14 and +28, following 7 days of labeling. Data for 3 independent experiments pooled for day +7 to +14 analysis, and 2 independent experiments for day +21 to +28 analysis. For panels A and C, n = 2–7 mice; for panels B and D, n = 5-8 mice; **P < 0.01; Tukey’s test with 2-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts